Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Begin-Period-Cashflow" stands at 37.04 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 06/30/2024.
Sanofi SA's third quarter result of 15.36 Billion EUR for the item "Begin Period Cashflow" represents an increase of 106.41 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 15.36 Billion EUR for the item "Begin Period Cashflow" represents an increase of 126.03 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 37.04 Billion EUR for the item "Begin Period Cashflow" represents an increase of 30.08 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 14.99 percent compared to the value the year prior.
The 1 year change in percent is 14.99.
The 3 year change in percent is 0.5948.
The 5 year change in percent is -11.32.
The 10 year change in percent is 404.51.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Begin Period Cashflow | 905,699,262,464.00 |
![]() | Johnson & Johnson - Begin Period Cashflow | 486,508,953,600.00 |
![]() | AbbVie Inc - Begin Period Cashflow | 399,570,305,024.00 |
![]() | Roche Holding AG - Begin Period Cashflow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Begin Period Cashflow | 280,205,508,085.11 |